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334subset of patients, the best choice could be the new
antiplatelet agents, either prasugrel or ticagrelor.*Gennaro Sardella, MD
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Variation Beyond Different Antiplatelet
Therapy in Nonresponder PatientsWe thank Drs. Sardella and Calcagno for their interest
in our paper (1). Following their prior publication (2),
they emphasize the importance of genotyping for the
CYP2C19*2 allele to deﬁne the pharmacodynamic
beneﬁt from prasugrel or double-dose clopidogrel in
patients with high platelet reactivity (HPR).
Although we share the belief that there is robust
evidence to declare that clopidogrel-treated patients
harboring CYP2C19*2 alleles are at higher risk for
stent thrombosis and mortality after percutaneous
coronary intervention (PCI) (3), we would be more
cautious to derive deﬁnite conclusions from a
subgroup of a study including 32 patients, which the
authors themselves declared “not powered for an
additive genetic model” (2).
To give an accurate answer to the authors’ ques-
tion, we had genotyping results available from the
ﬁrst 69 acute coronary syndrome (ACS) patients
with HPR. Based on the results, the proportions ofCYP2C19*2 carriers were exactly the same in both HPR
groups (HPRþprasugrel 46.2% vs. HPRþclopidogrel
46.6%), corroborating that the beneﬁt of prasugrel
over high-dose clopidogrel was not inﬂuenced by
differences in genotype status.
Finally, the authors claim it unethical to use
clopidogrel in patients with ST-segment elevation
myocardial infarction (STEMI). In current European
practice guidelines, prasugrel and ticagrelor are
preferred over clopidogrel in all ACS patients, not
only in case of STEMI (4,5). However, the guide-
lines also add that clopidogrel still holds a Class I
indication when prasugrel and ticagrelor are not
available. Similar to many countries in the world,
prasugrel and ticagrelor were not available in
Hungary for all ACS patients at the time of the
registry, and many clinicians were convinced that
using high-dose clopidogrel might effectively
replace the costly new P2Y12 inhibitors. Our ﬁndings
are therefore important to show that irrespective of
the genotype status, high-dose clopidogrel is asso-
ciated with a 3-fold higher risk for mortality or stent
thrombosis compared with prasugrel in ACS patients
with HPR.*Dániel Aradi, MD, PhD
András Komócsi, MD, DSc
*Heart Center Balatonfüred and Semmelweis University
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